These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38103657)

  • 1. Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2.
    Guareschi F; Del Favero E; Ricci C; Cantù L; Brandolini M; Sambri V; Nicoli S; Pescina S; D'Angelo D; Rossi I; Buttini F; Bettini R; Sonvico F
    Eur J Pharm Sci; 2024 Feb; 193():106673. PubMed ID: 38103657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poloxamer 407/TPGS Mixed Micelles as Promising Carriers for Cyclosporine Ocular Delivery.
    Grimaudo MA; Pescina S; Padula C; Santi P; Concheiro A; Alvarez-Lorenzo C; Nicoli S
    Mol Pharm; 2018 Feb; 15(2):571-584. PubMed ID: 29313693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
    Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures.
    Schütz D; Conzelmann C; Fois G; Groß R; Weil T; Wettstein L; Stenger S; Zelikin A; Hoffmann TK; Frick M; Müller JA; Münch J
    Am J Physiol Lung Cell Mol Physiol; 2021 May; 320(5):L750-L756. PubMed ID: 33561380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial.
    Lin Y; Yue S; Yang Y; Yang S; Pan Z; Yang X; Gao L; Zhou J; Li Z; Hu L; Tang J; Wu Q; Lei S; Tian Q; Wang Y; Hao Y; Xu L; Huang Q; Zhu B; Chen Y; Chen X; Ye L
    Clin Infect Dis; 2023 Feb; 76(3):e336-e341. PubMed ID: 35666466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Derived Nasal Spray; A Proposed Approach for COVID-19 Disease Control.
    Hoseini-Tavassol Z; Ejtahed HS; Soroush AR; Sajjadpour Z; Hasani-Ranjbar S; Larijani B
    Infect Disord Drug Targets; 2021; 21(8):e160921191568. PubMed ID: 33602078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation of a Composite Nasal Spray Enabling Enhanced Surface Coverage and Prophylaxis of SARS-COV-2.
    Moakes RJA; Davies SP; Stamataki Z; Grover LM
    Adv Mater; 2021 Jul; 33(26):e2008304. PubMed ID: 34060150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine-loaded micelles for ocular delivery: Investigating the penetration mechanisms.
    Ghezzi M; Ferraboschi I; Delledonne A; Pescina S; Padula C; Santi P; Sissa C; Terenziani F; Nicoli S
    J Control Release; 2022 Sep; 349():744-755. PubMed ID: 35901859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture.
    Bansal S; Jonsson CB; Taylor SL; Figueroa JM; Dugour AV; Palacios C; Vega JC
    PLoS One; 2021; 16(11):e0259943. PubMed ID: 34797868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration.
    Seow HC; Liao Q; Lau ATY; Leung SWS; Yuan S; Lam JKW
    Int J Pharm; 2022 May; 619():121704. PubMed ID: 35358643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies.
    Yu Y; Chen D; Li Y; Yang W; Tu J; Shen Y
    Drug Deliv; 2018 Nov; 25(1):888-899. PubMed ID: 29631468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19.
    Chavda VP; Patel AB; Vora LK; Singla RK; Shah P; Uversky VN; Apostolopoulos V
    Curr Pharm Des; 2022; 28(46):3658-3670. PubMed ID: 36284382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aqueous cannabidiol β-cyclodextrin complexed polymeric micelle nasal spray to attenuate in vitro and ex vivo SARS-CoV-2-induced cytokine storms.
    Changsan N; Sawatdee S; Suedee R; Chunhachaichana C; Srichana T
    Int J Pharm; 2023 Jun; 640():123035. PubMed ID: 37182795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization and Characterization of Aqueous Micellar Formulations for Ocular Delivery of an Antifungal Drug, Posaconazole.
    Durgun ME; Kahraman E; Güngör S; Özsoy Y
    Curr Pharm Des; 2020; 26(14):1543-1555. PubMed ID: 32167423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxypropyl Methylcellulose-Based Nasal Sprays Effectively Inhibit In Vitro SARS-CoV-2 Infection and Spread.
    Bentley K; Stanton RJ
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2.
    Meister TL; Todt D; Brüggemann Y; Steinmann J; Banava S; Brill FHH; Steinmann J; Pfaender S; Steinmann E
    J Hosp Infect; 2022 Feb; 120():9-13. PubMed ID: 34752803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers.
    Imsuwansri T; Jongthitinon T; Pojdoung N; Meesiripan N; Sakarin S; Boonkrai C; Wongtangprasert T; Phakham T; Audomsun T; Attakitbancha C; Saelao P; Muanwien P; Tian MT; Tongchusak S; Sangruji B; Wannigama DL; Sawangmake C; Rodprasert W; Le QD; Purbantoro SD; Vasuntrarak K; Nantavisai S; Sirilak S; Uppapong B; Sapsutthipas S; Trisiriwanich S; Somporn T; Usoo A; Mingngamsup N; Phumiamorn S; Aumklad P; Arunprasert K; Patrojanasophon P; Opanasopit P; Pesirikan N; Nitisaporn L; Pitchayakorn J; Narkthong T; Mahong B; Chaiyo K; Srisutthisamphan K; Viriyakitkosol R; Aeumjaturapat S; Jongkaewwattana A; Bunnag S; Pisitkun T
    Sci Rep; 2023 Sep; 13(1):15648. PubMed ID: 37730833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation.
    Seow HC; Cai JP; Pan HW; Luo C; Wen K; Situ J; Wang K; Cao H; Leung SWS; Yuan S; Lam JKW
    J Control Release; 2023 Jun; 358():128-141. PubMed ID: 37084889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astodrimer sodium nasal spray forms a barrier to SARS-CoV-2 in vitro and preserves normal mucociliary function in human nasal epithelium.
    Paull JRA; Luscombe CA; Seta A; Heery GP; Bobardt MD; Gallay PA; Constant S; Castellarnau A
    Sci Rep; 2024 Sep; 14(1):21259. PubMed ID: 39261670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.